The sharp guidance reduction for both Q3 and full-year 2026, combined with the recently announced $700M-$800M restructuring plan, signals a material growth deceleration and cost pressures. Traders should watch for further downside risk if Q3 guidance proves optimistic given the macro and tariff headwinds cited. The $1.5B MiRus investment and $2B buyback provide some offset but do not reverse the fundamental slowdown.
How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jul 29 $46.04entry
- T+1 · 4mo ago −0.09%α −1.76% · $46.00
- T+5 · 3mo ago +3.69%α −1.84% · $47.74
- T+20 · 3mo ago +4.63%α −0.39% · $48.17
- T+60 · 26d ago −0.07%α −4.79% · $46.01
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Boston Scientific reported Q2 2026 adjusted EPS of $0.86, beating the $0.83 consensus by 3.6%, on revenue of $5.442B (7.5% reported growth, above the 5.5-7.5% guidance range). However, the company significantly lowered full-year 2026 guidance: organic revenue growth cut to 5-6% (from prior 6.5-8%) and adjusted EPS guidance reduced to $3.28-$3.32 (from $3.34-$3.41). The beat was overshadowed by the guidance cut and a 2-day-old restructuring plan (Item 2.05) with $700M-$800M in charges, signaling a material deceleration in the core business.
Key Financial Metrics
Key Facts
- Q2 2026 adjusted EPS of $0.86 beat consensus of $0.83 by 3.6%
- Q2 revenue of $5.442B grew 7.5% reported, at the high end of 5.5-7.5% guidance
- Full-year 2026 organic revenue growth guidance slashed to 5-6% from prior 6.5-8%
- Full-year 2026 adjusted EPS guidance lowered to $3.28-$3.32 from $3.34-$3.41
- Q3 2026 organic revenue growth guided to just 3-5%, a sharp deceleration
- Completed $2B accelerated share repurchase, repurchasing ~40M shares
- Invested $1.5B for ~34% equity stake in MiRus LLC with option to acquire TAVR business
- Restructuring plan (filed 2 days ago) carries $700M-$800M in pre-tax charges through 2029
Financial Impact
Full-year revenue growth guidance cut by ~150-200bps; EPS guidance cut by $0.06-$0.09 per share
Risk Factors
- Further revenue deceleration in H2 2026 if Q3 guidance proves too optimistic
- Restructuring execution risk and potential for additional charges
- Tariff and geopolitical headwinds impacting international operations
- Integration risk from MiRus investment and potential future acquisition
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0000885725-26-000051 |
| Document: bsx-20260729.htm | 0000885725-26-000051 |
| Document: 0000885725-26-000051-index-headers.html | 0000885725-26-000051 |
| Document: 0000885725-26-000051-index.html | 0000885725-26-000051 |
| Document: 0000885725-26-000051.txt | 0000885725-26-000051 |
| 8-K Data (Synthetic) | 0000885725-26-000051 |
Track record
22 reports on BSX
4 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +9.24% at T+20 after the Aug 26, 2026 report. 6 of 8 went positive at some point.
Filters
- Oct 28, 202619d ago 8-K Bearish 6/10 No price data
- Oct 28, 202619d ago Press Release Bearish 5/10 Entry $42.43 Now $43.69 −2.97% settles Nov 25
- Oct 23, 202624d ago Institutional Cluster Bearish 4/10 Entry $45.69 Now $43.69 +4.38% settles Nov 20
- Oct 7, 20265w ago 8-K Mixed 6/10 Entry $41.58 to $45.82 Now $43.69 +5.07% ▲ +10.20% +11.54% vs SPY
- Sep 23, 20267w ago 8-K Bearish 5/10 Entry $44.62 to $44.51 Now $43.69 +2.08% ▲ +0.25% +0.93% vs SPY
- Aug 31, 202611w ago Court Ruling Neutral 2/10 Entry $48.08 to $43.65 Now $43.69 −9.13% ▼ −9.21% −9.57% vs SPY
- Aug 26, 202611w ago 8-K Bearish 6/10 Entry $48.17 to $43.72 Now $43.69 +9.30% ▲ +9.24% +10.44% vs SPY
- Aug 22, 202612w ago Institutional Cluster Mixed 6/10 Entry $49.01 to $44.92 Now $43.69 −10.85% ▼ −8.35% −9.66% vs SPY
- Aug 7, 202614w ago Insider Cluster Mixed 6/10 Entry $50.46 to $44.98 Now $43.69 −13.42% ▼ −10.86% −9.95% vs SPY
- Aug 7, 202614w ago Insider Cluster Mixed 5/10 Entry $50.46 to $44.98 Now $43.69 −13.42% ▼ −10.86% −9.95% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers